Premier Alternatives

GAIA BioMedicine

Fukuoka, Japan · Founded 2015 · Privately Held (backing)

Operator of a biopharmaceutical company intended to deliver cancer immuno-cell therapy. GAIA BioMedicine is based in Fukuoka, Japan and was founded in 2015. Its last reported valuation was $88.4 million in Jul 2025. It has raised $37.6 million.

Last reported valuation
$88.4M
Oct 2026
Priced at
—
Total raised
$37.6M
Last round
—

GAIA BioMedicine key facts

as of Oct 2026
  • Operator of a biopharmaceutical company intended to deliver cancer immuno-cell therapy.
  • GAIA BioMedicine is valued at approximately $88.4M as of Oct 2026 (last reported valuation).
  • It has raised $37.6M; the latest was Later Stage VC ($14.7M) in Jul 2025.
  • Notable investors include Mitsubishi UFJ Capital, SBI Investment, JIC Venture Growth Investments, UntroD, Osaka University Venture Capital — 10 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$88.4M

GAIA BioMedicine's last reported valuation, Jul 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of GAIA BioMedicine with a free Private Market View account
  • ·Watch GAIA BioMedicine: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

GAIA BioMedicine funding rounds

No rounds on record

No funding rounds for GAIA BioMedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

GAIA BioMedicine valuation

GAIA BioMedicine's last reported valuation was $88.4 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.

GAIA BioMedicine investors

10 investors are on record for GAIA BioMedicine, including Mitsubishi UFJ Capital, SBI Investment, JIC Venture Growth Investments and UntroD.

About GAIA BioMedicine

Operator of a biopharmaceutical company intended to deliver cancer immuno-cell therapy. The company offers antibody-anchoring peptide technology, tumor infiltration, and off-the-shelf cell formulations that help to eliminate solid tumors without genetic modification, enabling patients to fight intractable diseases using the power of genes and the immune system.

Sector
Healthcare
HQ
Fukuoka, Japan
Founded
2015
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.